Clinical Trials Update: Sept. 28, 2006
Adenocarcinoma Allergy HIV
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This study will evaluate whether patients treated with a combination of chemotherapy drugs (called "CHOP") and rituximab plus bevacizumab may have longer-lasting tumor shrinkage than patients treated with CHOP and rituximab alone. Volunteers may be included who are at least 60, who do not have uncontrolled hypertension, and who have previously untreated stage-III, -IV, or bulky stage-II diffuse large B-cell NHL, which is positive for CD-20.
The research site is in Elgin, Ill.
If you have had symptoms of hay fever for at least two years (sneezing; runny nose; itchy, watery, red eyes; itchy nose, palate, throat), you may be eligible to participate in this research study. Participants may receive study medication and will receive study-related physician visits, lab work, and financial compensation for time and travel.
The research site is in Salt Lake City, Ut.
This study will evaluate a two-drug combination to see it can help reverse metabolic complications of HIV lipodystrophy. Candidates at least 18 with documented HIV-1 infection who have had at least six months of stable cumulative antiretroviral therapy with any anti-retroviral medication (protease inhibitor, nucleoside reverse transcriptase inhibitor, non-nucleoside reverse transcriptase inhibitor, nucleotide reverse transcriptase inhibitor) may qualify.
People with a history of impaired glucose metabolism or hyperlipidemia prior to antiretroviral use or abnormal hepatic function (liver function tests higher than twice the upper normal range) will not be included.
The research site is in Boston, Mass.
Copyright 2006 Thomson CenterWatch. All rights reserved.